Patients will be selected from the MORE Registry according to the inclusion/exclusion criteria. Four different cohorts will be evaluated: patients who were prescribed warfarin, apixaban, dabigatran or rivaroxaban. Only users of oral anticoagulant treatment from January 1, 2013 to January 1, 2016 will be included in this study.